Other

Dataset Information

0

Azithromycin effects on lung microbiome in COPD patient


ABSTRACT: Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in chronic obstructive pulmonary disease patients with emphysema. The antimicrobial effects of AZM on the lung microbiome are not known and may contribute to its beneficial effects. Methods. Twenty smokers with emphysema were randomized to receive AZM 250 mg or placebo daily for 8 weeks. Bronchoalveolar lavage (BAL) was performed at baseline and after treatment. Measurements included: rDNA gene quantity and sequence. Results. Compared with placebo, AZM did not alter bacterial burden but reduced α-diversity, decreasing 11 low abundance taxa, none of which are classical pulmonary pathogens. Conclusions. AZM treatment the lung microbiome

ORGANISM(S): human lung metagenome

PROVIDER: GSE74396 | GEO | 2016/07/19

SECONDARY ACCESSION(S): PRJNA300280

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2016-07-19 | E-GEOD-74396 | biostudies-arrayexpress
2018-11-14 | GSE119314 | GEO
2009-05-01 | GSE12738 | GEO
2004-08-08 | GSE1650 | GEO
2021-06-08 | GSE173073 | GEO
2020-12-21 | GSE151259 | GEO
2019-11-07 | E-MTAB-8488 | biostudies-arrayexpress
2021-03-21 | GSE112165 | GEO
2016-01-22 | GSE69818 | GEO
2019-06-27 | GSE128523 | GEO